Healthcare TB
Healthcare TB

Chimeric Antigen Receptor (CAR) T Cell Immunotherapy -Pipeline Insights 2017

Date: July 2017   Number of Pages: 70 
Geography:  Global Delivery Timeline: 6-7 Business Days
StumbleUponEmail
SKU: HPA1707-02 Category:

Product Description

Chimeric Antigen Receptor (CAR) T Cell Immunotherapy 

CAR-T cell immunotherapy represents one of a major breakthrough in cancer research.For decades, the cornerstones of cancer treatment have been chemotherapy, surgery, and radiation therapy. Over the past decade, targeted therapies like trastuzumab (Herceptin) and imatinib (Gleevec) – drugs that target cancer cells by homing in on specific molecular changes observed primarily in those cells have also become standard treatment options for various types of cancer. Currently, research and development around anti-cancer immunotherapies is on rise. These therapies hold a potential to harness the utilize patients’ own immune system to combat diseases.

The CAR-T cell therapy, a form of immunotherapy, is a novel adoptive antitumor treatment. Ideally, CAR-T cells can particularly localize and destroy tumor cells by interacting with the tumor specific antigens located on surface of tumor cell. Current research studies showed that various tumor specific antigens can act as target antigensfor CAR-T cells, for instance, the type III variant epidermal growth factor receptor and human epidermal growth factor receptors are considered as ideal targets for its aberrant expression on the cell surface of various tumor types.

CAR-T cell therapy showed promising results in the treatment of haematological malignancies and solid tumors. The third generation of CAR-T cell therapy demonstrates increased antitumor cytotoxicity and persistence through modifying the structureof CAR-T cells. In this report, we mentioned the preclinical and clinical progress of CAR-T cells targeting various variants including EGFR, human epidermal growth factor receptor 2 (HER2), and mesothelin (MSLN).

The manufacturing of CD19 CAR T cell immunotherapy CTL019 is in a way which will reform the process of using the CAR T cell therapy globally. The anticipation of regulatory and manufacturing challenges before they rise and proactively addressing the disquiets helps to hasten the process of bringing this promising novel approach to more patients in future. Few of other promising CAR T cell candidates currently in the pipeline are KTE-C19, JCAR020, JCAR 024, JCAR015, JCAR017, UCART19, S68587, UCART123, MB-101, bb2121, PCAR-119, anti-CD19 CAR-NK cells, MB-102, AU-101, huCART19, huCTL019, BPX-401 (CIDeCAR), OXB-302, ICG-122, CD4CAR, ICG-124, CD5CAR, ICG-142, ICG-140, ICG-138/ICG-139, ICG-136.

Scope of The Report

The report provides

 

  • Provides in-depth insights about active Chimeric Antigen Receptor (CAR) T cell pipeline drug candidates

  • Offers an extensive pipeline product coverage with demarcation by various stages of development from NDA filings to discovery

  • Provides pipeline assessment by cancer type

  • Includes coverage of detailed pipeline drug profiles, which include product description, chemical information, MOA, licensors and collaborators, development partner

  • Analyzes key players involved in clinical research and development of the Chimeric Antigen Receptor (CAR) T cell immunotherapy

  • Provides the coverage of key news related to Chimeric Antigen Receptor (CAR) T cell immunotherapy, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates

Why should you buy the report?

  • To gain erudite insights about the Chimeric Antigen Receptor (CAR) T cell immunotherapypipeline landscape
  • To ascertain unique product development dynamics and leverage it for new target identification, drug repositioning, and precision medicine
  • To optimize the pipeline product portfolio in correspondence with the dynamic pharmaceutical market
  • To identify competitors and design strategic initiatives for drug development activities
  • To understand the market and choose right partners for strategic collaborations
  • To obtain informed updates on drug termination/drug discontinuation

The “Chimeric Antigen Receptor (CAR) T cell Immunotherapy -Pipeline Insights 2017″ report provides a comprehensive analysis of CAR-T cell profiles currently undergoing clinical studies. It covers detailed drug profiles of potential CAR-T across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent, and USFDA and EMA designations. It also assesses the pipeline CAR-T cell immunotherapies by cancer type. In addition to analysis on active pipeline molecules, the report also provides a detailed information about discontinued and dormant drugs.

The report profiles key players in developing potential CAR T cell Immunotherapy candidates. The company profile section provides details such as company overview, business overview, financial overview, product portfolio, business strategies, and recent developments.

SECTION  1: Executive Summary
 
SECTION  2: Scope of the Report
 
SECTION  3: Introduction
  • Chimeric Antigen Receptor (CAR) T cell immunotherapy– Overview
  • Chimeric Antigen Receptor (CAR) T cell immunotherapy–Role in cancer treatment
 
SECTION  4: Chimeric Antigen Receptor (CAR) T cell immunotherapy– Pipeline Landscape
  • Overview of Pipeline Chimeric Antigen Receptor (CAR) T cell immunotherapy
  • Chimeric Antigen Receptor (CAR) T cell immunotherapyFiled and Phase III Products
  • Comparative Analysis 
  • Chimeric Antigen Receptor (CAR) T cell immunotherapy Phase II Products
  • Comparative Analysis 
  • Chimeric Antigen Receptor (CAR) T cell immunotherapyPhase I and IND Filed Products
  • Comparative Analysis 
  • Chimeric Antigen Receptor (CAR) T cell immunotherapyDiscovery and Pre -Clinical Stage Products 
  • Comparative Analysis 
  • Chimeric Antigen Receptor (CAR) T cell immunotherapy – Technologies & Companies Involved
  • CAR-T cells Targeted Antigens
  • Chimeric Antigen Receptor (CAR) T cell immunotherapy- Discontinued Products 
 
SECTION  5: Global CAR T Cell Therapy Trials for Cancer Treatment
  • Solid Tumors 
  • Haematological malignancies
 
SECTION  6:  FDA Granted Breakthrough Therapies
  • FDA granted breakthrough therapy for CTL019, the anti-CD19 CAR T-cell therapy developed at the University of Pennsylvania, Novartisto destroy b-cell cancers
 
SECTION  7: Companies with Upcoming CAR-T cell immunotherapy
 
SECTION  8: Comparative Analysis of Pipeline Chimeric Antigen Receptor (CAR) T cell immunotherapy
 
SECTION  9: Key Pipeline Product Profiles
 
Section  10: Competitive Landscape
  • Key Company Profiles
 
Section  11: Key News
  • Major Mergers and Acquisitions
  • Product News (including clinical trial progression updates)
List of Tables
 
• Pipeline Chimeric Antigen Receptor (CAR) T cell immunotherapyCandidates by Therapy Area 2017
• Comparative Analysis by Filed and Phase III Products 2017
• Comparative Analysis Phase II Products 2017
• Comparative Analysis Phase I and IND Filed Products 2017
• Comparative Analysis Discovery and Pre-Clinical Stage Products 2017
• Chimeric Antigen Receptor (CAR) T cell immunotherapy– Discontinued Products 
• Chimeric Antigen Receptor (CAR) T cell immunotherapy– Dormant Products
• Chimeric Antigen Receptor (CAR) T cell immunotherapyAssessment by Cancer Types
• Comparative Analysis Marketed and Pipeline Chimeric Antigen Receptor (CAR) T cellimmunotherapy
  • Drug Candidates Profiles
List of Figures
 
• Pipeline Chimeric Antigen Receptor (CAR) T cell immunotherapyCandidates by Therapy Area 2017
• Chimeric Antigen Receptor (CAR) T cell immunotherapy– Filed and Phase III Products 2017
• Chimeric Antigen Receptor (CAR) T cell immunotherapy– Phase II Products 2017
• Chimeric Antigen Receptor (CAR) T cell immunotherapy– Phase I and IND Filed Products 2017
• Chimeric Antigen Receptor (CAR) T cell immunotherapy– Discovery and Pre-Clinical Stage Products 2017
• Tumor Necrosis Factor Alpha (TNF-a) Inhibitors Assessment by cancer type 
 





Reviews

There are no reviews yet.

Be the first to review “Chimeric Antigen Receptor (CAR) T Cell Immunotherapy -Pipeline Insights 2017”

Request Call Back
Request Call Back
Need Custom Report?
click here

Our Services

  • Beige Market Intelligence - Syndicated Research Reports

  • Beige Market Intelligence - Market Research and Custom Research

  • Beige Market Intelligence - Business Consulting